> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# ImmunityBio Targets Earlier Bladder Cancer Treatment After ANKTIVA Combination Outperforms BCG Alone
- URL: https://www.bullished.co/immunitybio-targets-earlier-bladder-cancer-treatment-after-anktiva-combination-outperforms-4d5088a3/
- Published: 2026-11-09T11:56:05.000Z
- Updated: 2026-11-09T11:56:05.000Z
- Description: The company targets an FDA application by year-end 2026 to reach patients receiving BCG for the first time.
- Author: Matteo Parrino
- Tags: SEC Filings, IBRX, Industry: Healthcare

[ImmunityBio](https://www.bullished.co/tag/ibrx/), which develops and sells immune-system treatments for cancer and infectious diseases, said Monday that ANKTIVA combined with BCG [outperformed BCG alone](https://www.businesswire.com/news/home/20261109448906/en/ImmunityBio-Announces-ANKTIVA-Plus-BCG-Meets-Primary-Endpoint-in-BCG-Nave-Non-Muscle-Invasive-Bladder-Cancer-Randomized-QUILT-2.005-Trial?ref=bullished.co) in a randomized bladder-cancer trial, meeting its main goal. The company remains on track to seek FDA approval by year-end 2026 for use in patients starting BCG treatment, earlier than the population covered by its existing bladder-cancer approvals.

## A Test In Earlier Treatment

The trial enrolled 370 randomized patients with high-grade bladder cancer that had not invaded the bladder muscle. The final analysis for the group with carcinoma in situ, with or without papillary tumors, found a statistically significant efficacy improvement from adding ANKTIVA to BCG, a standard bladder-cancer treatment, according to the company's trial announcement.

The chemotherapy-free combination is delivered directly into the bladder. Participants were receiving BCG-based therapy for the first time; ANKTIVA's current bladder-cancer use covers patients whose disease does not respond to BCG.

Enrollment finished in February 2026\. An independent monitoring committee reviewed the trial in March 2026 and determined that further enrollment was unnecessary to preserve the planned statistical power. [More than 75 sites](https://www.businesswire.com/news/home/20261109448906/en/ImmunityBio-Announces-ANKTIVA-Plus-BCG-Meets-Primary-Endpoint-in-BCG-Nave-Non-Muscle-Invasive-Bladder-Cancer-Randomized-QUILT-2.005-Trial?ref=bullished.co) participated, with US Urology Partners, Dartmouth-Hitchcock and University of California Los Angeles enrolling the most patients.

## Response Durability And Safety

Patients' self-reported quality of life held steady during combination treatment. The median duration of response had not been reached, meaning the midpoint of how long responses lasted was still undetermined at the analysis.

The most frequent side effects emerging during treatment, including those attributed to treatment, resembled those seen with BCG alone. The company reported no treatment-related deaths.

Christopher Pieczonka, corporate director of clinical research at U.S. Urology Partners and the trial's global principal investigator, described the potential patient benefit in the release: “By improving responses earlier in the disease course, this combination has the potential to help more patients remain disease-free longer, avoid additional treatments.”

The results remain distinct from regulatory approval. ImmunityBio cautioned that response durability could change with continued follow-up and that the trial's open-label design could affect whether the findings support approval.

## Expanding ANKTIVA's Patient Base

ANKTIVA generated about $113 million in net sales in 2025 and is ImmunityBio's main commercial product. The company also has vaccines and natural killer cell therapies in development.

The ANKTIVA-BCG combination received approval in April 2024 for BCG-unresponsive carcinoma in situ, with or without papillary disease. Its approved use expanded in October 2026 to cover BCG-unresponsive disease including both carcinoma in situ and papillary disease. The planned application would seek to move treatment earlier, rather than simply extend use within that existing population.

Patrick Soon-Shiong, ImmunityBio's founder, executive chairman and global chief scientific and medical officer, said: “The statistically significant improvement in efficacy supports our efforts to extend this therapeutic approach to patients earlier in their treatment journey.”

ImmunityBio plans to present further trial findings at an upcoming medical congress. Its next regulatory target is submitting the FDA approval application by year-end 2026.

Learn

- [Item 7.01: Regulation FD disclosure →](https://www.bullished.co/learn/8-k-items-explained/#item-701-regulation-fd-disclosure)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — ImmunityBio, Inc. (IBRX)](https://www.sec.gov/Archives/edgar/data/0001326110/000132611026000091/ibrx-20261109.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit ibrx-20261198xkexhibit991.htm — ImmunityBio, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001326110/000132611026000091/ibrx-20261198xkexhibit991.htm?ref=bullished.co) — SEC EDGAR
- [ImmunityBio (IBRX) Could Be 42% Below Fair Value After Trial Database Lock](https://sg.finance.yahoo.com/news/immunitybio-ibrx-could-42-below-190916038.html?ref=bullished.co) — Yahoo Finance
- [ImmunityBio Treats First Patients In Europe With Anktiva Plus BCG – Retail Calls It A ‘Great Opening Act’ For Q3 Earnings](https://finance.yahoo.com/healthcare/articles/immunitybio-treats-first-patients-europe-152330997.html?ref=bullished.co) — Yahoo Finance
- [How Investors May Respond To ImmunityBio (IBRX) Europe Launch And Trial Progress](https://sg.finance.yahoo.com/news/investors-may-respond-immunitybio-ibrx-201257432.html?ref=bullished.co) — Yahoo Finance
- [IBRX Stock Climbs Overnight: Founder Calls Sepsis Push ‘Unstoppable’ As Trials Near — Teases NantX After Crypto Heist](https://finance.yahoo.com/healthcare/articles/ibrx-stock-climbs-overnight-founder-044415361.html?ref=bullished.co) — Yahoo Finance
- [ImmunityBio Announces ANKTIVA® Plus BCG Meets Primary Endpoint in BCG-Naïve Non-Muscle Invasive Bladder Cancer Randomized QUILT-2.005 Trial](https://www.businesswire.com/news/home/20261109448906/en/ImmunityBio-Announces-ANKTIVA-Plus-BCG-Meets-Primary-Endpoint-in-BCG-Nave-Non-Muscle-Invasive-Bladder-Cancer-Randomized-QUILT-2.005-Trial?ref=bullished.co) — businesswire.com

### More on ImmunityBio

- [ImmunityBio Says FDA Widened Anktiva's Label To Papillary-Only Bladder Cancer, A Group It Puts At About 85% Of Patients](https://www.bullished.co/immunitybio-says-fda-widened-anktivas-label-to-papillary-only-bladder-cancer-a-group-it-6454e5a0/)

[All ImmunityBio (IBRX) coverage →](https://www.bullished.co/tag/ibrx/)